zur Navigation zum Inhalt
Onkologie 12. Oktober 2016

Acute myeloid leukemia: highlights from ASH 2015

Despite of the progress achieved in recent years for acute myeloid leukemia (AML) treatment, there is still a need for improvement, both for younger and elderly patients. This review covers studies for AML presented at the ASH 2015 annual meeting. The presentations selected offer a glimpse of the future of AML treatment. Also in AML insights into the molecular pathogenesis can be translated into clinical practice where a major step has been set with the first positive trial with respect to overall survival for the tyrosine kinase inhibitor midostaurin. Also for older patients, unfit for chemotherapy, therapy options are increasingly available. Individualized therapies will require both new trial designs and new approaches for patient assessment and clinical decision making.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben